期刊
EUROPEAN UROLOGY FOCUS
卷 4, 期 4, 页码 509-511出版社
ELSEVIER
DOI: 10.1016/j.euf.2018.08.005
关键词
Bladder cancer; Urothelial cancer; Photodynamic therapy; Photoimmunotherapy; PDT; PIT; Hematoporphyrin; 5-Aminolevulinic acid; Hexaminolevulinic acid; BCG-refractory NMIBC
资金
- Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research
There are limited treatment options for patients with recurrent non-muscle-invasive bladder cancer. In this report, we will talk about the history of photodynamic therapy; although it showed encouraging therapeutic results, it was largely abandoned due to toxicity or bystander effects on normal cells. Monoclonal antibody-conjugates represent an emerging therapeutic approach for malignancies that improves upon tumor specificity. The use of a monoclonal antibody-photosensitizer conjugate is a more selective method of delivering light therapy and has been termed photoimmunotherapy, which we will discuss in the last part of this report. (C) 2018 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据